MedTrace Logo

Visual Outcomes After Vivity Toric IOL Implantation

NCT04675489 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2022-01-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate patient satisfaction after bilateral implantation of Vivity Toric Extended Vision Intraocular lens and visual outcomes.

Conditions

  • Refractive Assessment

Interventions

OTHER

Procedure: Vivity Toric IOL

The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's Vivity Toric Extended Vision intraocular lens (IOL) for cataract patients. This innovative lens is an extended depth of focus IOL that has been reported to result in fewer visual disturbances than diffractive IOLs.

Sponsors & Collaborators

  • Alcon Research

    collaborator INDUSTRY

  • Icon Eye Care

    collaborator OTHER

  • EVP Eye Care

    lead OTHER

Principal Investigators

  • James Fox, MD · Icon Eye Care

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-15
Primary Completion
2021-12-13
Completion
2021-12-13

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04675489 on ClinicalTrials.gov